deltatrials

Early breast cancer Trials in Barcelona, Spain

Conditions / Early breast cancer / Barcelona, Spain

Research into Early breast cancer spans multiple therapeutic approaches and trial phases.

10 total trials for this combination

Trials

NCT ID Title Status Phase
NCT05217381 Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status COMPLETED
NCT04733118 Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer ACTIVE_NOT_RECRUITING
NCT04961996 A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) ACTIVE_NOT_RECRUITING PHASE3
NCT03493854 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer COMPLETED PHASE3
NCT02308085 Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer ACTIVE_NOT_RECRUITING NA
NCT04436744 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) COMPLETED PHASE2
NCT01792726 A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer. UNKNOWN NA
NCT04733118 Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer ACTIVE_NOT_RECRUITING
NCT03701334 A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer ACTIVE_NOT_RECRUITING PHASE3
NCT06690489 An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast Cancer Treated With Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events) COMPLETED

Related Pages